Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

asx pxs

  • Home
  •  
  • asx pxs



  • Most Read
  • Latest Comments
  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients
    Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients
    • News

  • Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%
    Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%
    • News

  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • News

  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • News

  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars

    Beyond the searing pain of burns, permanent scarring of the skin has a devastating lifelong impact on quality of life. Imagine reaching up for the top shelf and having a sharp pain surge down your arm and back. Unfortunately this is the reality for millions of burn victims where skin does not heal with the

    Read More
    Public
  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • News

    First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease

    Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with the first Australian patient in a Phase 2 clinical trial having been dosed with PXS-4708, a novel drug aimed at tackling  Parkinson’s before its onset, along with other neurodegenerative disorders. The multi-national trial was initiated

    Read More
    Public
  • Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
    • News

    Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma

    With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with the sale of its mannitol respiratory business (MBU) and will now will focus their resources towards a much larger commercial opportunity in blood cancers haematological malignancies, aka blood cancers.  The definitive sale agreement of its

    Read More
    Public
  • Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%
    • News

    Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%

    Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose and with limited treatment options. Thanks to a new study conducted by the Garvan Institute of Medical Research, however, a drug developed by biotech company Pharmaxis (ASX: PXS) could increase patient survival rates by 35%. 

    Read More
    Public
  • Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials
    • News

    Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials

    Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis (ASX: PXS) has quickly jumped forward in the commercialisation process having been cleared by the US Food and Drug Administration (FDA) to commence a combination arm of the trial. The clearance of the amended trial

    Read More
    Public
  • Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions
    • News

    Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions

    In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the final interim data analysis of their Phase 2 clinical trials for PXS-5505, a promising drug aimed at combating the debilitating effects of myelofibrosis.  The data revealed 60% of trial patients experienced a significant improvement in

    Read More
    Public
  • 1
  • 2
  • 3
  • 4
  • 5

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.